News

The treatments also led to a decrease in the density of immunohistochemistry of sweat glands.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Patients given LNK01001 showed significant improvement in EASI scores over placebo.

Research showed that many patients with skin cancer who had been treated using immunotherapy, such as immune checkpoint inhibition, experienced chronic side effects.

Dermatology Times is counting down to the annual fall SDPA conference in Nashville, Tennessee, with our top 10 headlines and highlights from this year's summer conference.

With hormonal fluctuations, constantly changing schedules, and various afterschool activities, addressing the specific needs of teenage skin becomes essential to promote a lifetime of proper skin care practices.

This week’s collection of the latest dermatologic studies covers an evaluation of the human stratum corneum with confocal Raman micro-spectroscopy, anti-mBP180 antibodies from mice, an updated review of alopecia areata comorbidities, and an ecchymotic patch related to chronic lymphocytic leukemia.

A grant from the National Institutes of Health will support continued research to develop products for soft tissue regeneration.

In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.

Researchers conducted systematic mapping of relevant DHI literature to determine the impact of these interventions on dermatologic care outcomes.

The guidance draft, once finalized, will enable the US FDA to have more oversight in the realm of cosmetic safety.

Clinically asymptomatic patients receiving alternative to conventional follow-up had a higher 3-year overall survival rate.

From bug bites to poison ivy, the skin can be exposed to a large spectrum of trouble while patients spend extended time outside.

In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about sunscreen use.

Clinicians can focus on patient care and leave human resources and bookkeeping to office staff.

Studies showed the various treatments improved symptoms, but more trials need to be done.

During the 25th World Congress of Dermatology, 40 rising stars and personalities were spotlighted for their contributions to the field.

This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.

More understanding of the physical, psychological, and economic burdens of hyperhidrosis is needed.

Few adverse events resulted from treatment with dupilumab in 64 weeks of observation.

Keep up with the latest headlines in dermatology from the past week, including cercarial dermatitis cases popping up across beaches in Connecticut, reports of Florida dermatologists encountering patients with leprosy, and more.

Leading atopic dermatitis experts delve into integrative approaches, prescription options, and strategies to encourage patients to stick with their treatment plan.

ICYMI, this week we had stories about laser treatments for port wine stain birthmarks, Abeona's briefing package filing for the BLA for its anticipated epidermolysis bullosa drug, using digital apps to detect skin cancers, and more.

The effects of the serum, Refine, can be seen in 6 to 12 months.

The fractional picosecond laser had a lower incidence of adverse events compared to fractional lasers.

The most common comorbidities identified included anxiety, dermatitis, hyperthyroidism, hyperlipidemia, and vitamin D deficiency.

While both cryotherapy and plasma exeresis are effective in clearing seborrheic keratosis lesions, researchers observed more statistically significant clearance in patients treated with plasma exeresis.

Clinicians can offer specials to patients, encouraging them to try new products or return for a refresh.

In this week’s Pointers With Portela, the 208SkinDoc reviews the benefits of oral minoxidil for hair loss.

"The analysis showed a statistically significant, positive effect of normal serum vitamin D levels on increasing ORR and PFS as a result of anti-PD‐1 immunotherapy in patients with locally advanced inoperable or metastatic melanoma,” according to a recent study.